Banque Cantonale Vaudoise Acquires New Stake in Moderna, Inc. (NASDAQ:MRNA)

Key Points

• Banque Cantonale Vaudoise has acquired a new stake in Moderna, Inc., purchasing 14,589 shares worth approximately $413,000 during the first quarter.
• Despite recent investments, Moderna's stock has seen a decline of 6.6%, with current trading at $27.60 and a notable 1-year high of $91.99.
• Moderna reported a quarterly loss of ($2.13) EPS, surpassing estimates, with revenue of $142 million but down 41.1% year-over-year.

Banque Cantonale Vaudoise acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 14,589 shares of the company's stock, valued at approximately $413,000.

Several other institutional investors have also recently added to or reduced their stakes in MRNA. Deutsche Bank AG boosted its holdings in Moderna by 54.7% in the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after acquiring an additional 669,614 shares during the last quarter. Tang Capital Management LLC acquired a new position in Moderna in the 4th quarter worth $12,474,000. Bank of New York Mellon Corp lifted its holdings in Moderna by 1.8% in the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock worth $54,382,000 after buying an additional 34,034 shares in the last quarter. Wealthfront Advisers LLC lifted its holdings in Moderna by 143.3% in the 1st quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock worth $879,000 after buying an additional 18,268 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd boosted its holdings in shares of Moderna by 73.5% during the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 40,772 shares of the company's stock valued at $1,156,000 after acquiring an additional 17,268 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Down 6.6%

NASDAQ MRNA opened at $27.60 on Friday. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $91.99. The company has a market capitalization of $10.67 billion, a PE ratio of -3.16 and a beta of 1.83. The firm's fifty day simple moving average is $29.22 and its 200-day simple moving average is $30.29.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The business had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same quarter in the previous year, the business earned ($3.33) EPS. Moderna's quarterly revenue was down 41.1% compared to the same quarter last year. As a group, analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. William Blair reiterated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Royal Bank Of Canada dropped their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday. Citigroup started coverage on Moderna in a research report on Friday. They set a "neutral" rating and a $40.00 target price on the stock. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Four investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Moderna currently has an average rating of "Hold" and an average target price of $46.11.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.